Loading clinical trials...
Loading clinical trials...
A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia
Conditions
Interventions
Venetoclax
Ibrutinib
Locations
15
United States
Dana-Farber Cancer Institute /ID# 207728
Boston, Massachusetts, United States
Mayo Clinic - Rochester /ID# 207692
Rochester, Minnesota, United States
University of Texas MD Anderson Cancer Center /ID# 207746
Houston, Texas, United States
Peter MacCallum Cancer Ctr /ID# 209554
Melbourne, Victoria, Australia
Medizinische Universitaet Wien /ID# 208497
Vienna, State of Vienna, Austria
Helsinki University Hospital /ID# 208108
Helsinki, Uusimaa, Finland
Start Date
January 14, 2020
Primary Completion Date
November 4, 2021
Completion Date
November 4, 2021
Last Updated
December 19, 2022
NCT05468034
NCT06735690
NCT04541381
NCT05398783
NCT07489378
NCT06713993
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions